From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With Emerging Solutions



Date & Location
Thursday, June 12, 2025, 8:00 AM - Thursday, June 11, 2026, 11:59 PM

Credits
AMA PRA Category 1 Credits™ (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)

Target Audience
Specialties - Dermatology
Professions - Advanced Practice Provider (APP), Non-Physician, Nurse, Other Healthcare Professionals, Physician, Physicians In Training

Overview

Uncontrolled chronic spontaneous urticaria (CSU) can lead to persistent and severe pruritus, sleep disruption, and anxiety, significantly impairing quality of life. Standard therapies often fail to deliver effective, durable relief. However, new insights into CSU’s immune-mediated pathways have opened the door to more personalized care, including biomarker-driven diagnosis, classification, and treatment. Among emerging therapies, Bruton tyrosine kinase (BTK) inhibitors show promise in patients unresponsive to maximized antihistamines. These agents act quickly and have demonstrated efficacy and tolerability.

This PeerView Cases activity uses a real-world clinical scenario to navigate current challenges in CSU management. Through a video-based format, it highlights key prognostic biomarkers, reviews the latest clinical data on BTK inhibitors, and presents evidence-based strategies for optimizing care—emphasizing multidisciplinary approaches that address both physical and psychosocial patient needs.


Registration

There are no fees for participating in and receiving CME credit for this online activity.

To view this activity, click this link, or visit the content tab.


Objectives
As a result of participating in this activity, participants should be able to:

  1. Identify the key prognostic biomarkers used in the diagnosis and assessment of CSU;
  2. Assess the latest clinical trial data surrounding emerging therapies, such as BTK inhibitors, for the treatment of CSU;
  3. Implement optimal strategies for the treatment of CSU based on evolving clinical evidence with respect to emerging agents;
  4. Develop multidisciplinary care plans for CSU patients that address both the physical and psychosocial aspects of the disease, ensuring comprehensive management of the condition.

Accreditation

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 CreditTM. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.


Additional Information

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

All relevant relationships have been mitigated. The following disclosures were made:

Medical Director & Program Planners

PVI, PeerView Institute for Medical Education

Kim Nealy, PharmD, Medical Director
Laura Cooney, Managing Editor
Megan Cowell, Senior Educational Program Director
Alisha Roepke, Senior Educational Program Manager

University of Cincinnati Center for Continuous Professional Development/CME

Robert V. Ellis, MD Physician Reviewer
Jackie Knapke, PhD, Associate Dean
Heather Muskopf, Program Director

The University of Cincinnati and PeerView staff and reviewers do not have any relationships to report.

Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.